Viewing Study NCT01245166


Ignite Creation Date: 2025-12-24 @ 4:37 PM
Ignite Modification Date: 2025-12-30 @ 3:54 PM
Study NCT ID: NCT01245166
Status: UNKNOWN
Last Update Posted: 2010-11-22
First Post: 2010-11-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Sponsor: Lotus Pharmaceutical
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module